Radioimmunoimaging for Diagnosis of Bone Marrow Involvement in Breast Cancer and Malignant Lymphoma

Reske, S. N.; Gloeckner, Wolfgang; Schwarz, A.; Karstens, J.H.; Steinsträsser, A; Ammon, J.; Buell, Udalrich

doi:10.1016/s0140-6736(89)91309-3

Cited by 75 publications

(36 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For radioimmunotherapy of leukemia, antibodies directed to the antigens CD33, CD45, and CD66 have been extensively investigated (3). Several studies with radiolabeled anti-CD66 antibody have been conducted so far (5)(6)(7)(8)(9)(10)(11)(12)(13).…”

mentioning

confidence: 99%

Radioimmunotherapy with Anti-CD66 Antibody: Improving the Biodistribution Using a Physiologically Based Pharmacokinetic Model

Kletting¹,

Kull²,

Bunjes³

et al. 2010

J Nucl Med

View full text Add to dashboard Cite

To improve radioimmunotherapy with anti-CD66 antibody, a physiologically based pharmacokinetic (PBPK) model was developed that was capable of describing the biodistribution and extrapolating between different doses of anti-CD66 antibody. Methods: The biodistribution of the 111 In-labeled anti-CD66 antibody of 8 patients with acute leukemia was measured. The data were fitted to 2 PBPK models. Model A incorporated effective values for antibody binding, and model B explicitly described mono-and bivalent binding. The best model was selected using the corrected Akaike information criterion. The predictive power of the model was validated comparing simulations and 90 Y-anti-CD66 serum measurements. The amount of antibody (range, 0.1-4 mg) leading to the most favorable therapeutic distribution was determined using simulations. Results: Model B was better supported by the data. The fits of the selected model were good (adjusted R 2 . 0.91), and the estimated parameters were in a physiologically reasonable range. The median deviation of the predicted and measured 90 Y-anti-CD66 serum concentration values and the residence times were 24% (range, 17%231%) and 9% (range, 1%264%), respectively. The validated model predicted considerably different biodistributions for dosimetry and therapeutic settings. The smallest (0.1 mg) simulated amount of antibody resulted in the most favorable therapeutic biodistribution. Conclusion: The developed model is capable of adequately describing the anti-CD66 antibody biodistribution and accurately predicting the time-activity serum curve of 90 Yanti-CD66 antibody and the therapeutic serum residence time. Simulations indicate that an improvement of radioimmunotherapy with anti-CD66 antibody is achievable by reducing the amount of administered antibody; for example, the residence time of the red marrow could be increased by a factor of 1.9 6 0.3 using 0.27 mg of anti-CD66 antibody.

show abstract

mentioning

confidence: 99%

Radioimmunotherapy with Anti-CD66 Antibody: Improving the Biodistribution Using a Physiologically Based Pharmacokinetic Model

Kletting¹,

Kull²,

Bunjes³

et al. 2010

J Nucl Med

View full text Add to dashboard Cite

show abstract

“…Since granulopoetic bone marrow cells are 50 to 100 tines more frequent than granulocytes in peripheral blood (22), TcNCAA distributes primarily to the bone marrow after i.v. injection (12,13). Immunohistology and flow cytometry of human bone marrow showed selective TcNCAA-binding to granulopoetic cells both after in vitro incubation with TcNCAA and after TcNCAA injection i.v.…”

Section: Antibodymentioning

confidence: 98%

“…We have recently used a monoclonal antibody that binds to granulopoetic cells in bone marrow (12,13) and to granulocytes in peripheral blood (14,15) for the immunoscintigraphic examination of haematopoetic bone marrow in humans (12,13). High-quality scans showing the distribution of haematopoetic bone marrow were consistently obtained (12,13).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Bone Marrow Immunoscintigraphy Compared with Conventional Bone Scintigraphy for the Detection of Bone Metastases

Reske¹,

Kartsens²,

Sohn³

et al. 1993

Acta Oncologica

Self Cite

View full text Add to dashboard Cite

“…23,27 The anti-CD66 antibody (antigranulocyte, anti-nonspecific cross-reacting antigen 95; BW 250/183) is well characterized with respect to biokinetic data and clinical application in bone marrow (BM) scintigraphy. [28][29][30] Yttrium-90 ( 90 Y) is a ␤-particle emitter with a high energy (2.3 MeV), a maximum range of the ␤ particles of 11 mm, and a half-life of 2.7 days. 31 90 Y administration does not require isolation of patients because it does not emit ␥ radiation.…”

Section: Drug Administration and Preparative Regimen Before Hctmentioning

confidence: 99%

Radioimmunotherapy-based conditioning for hematopoietic cell transplantation in children with malignant and nonmalignant diseases

Schulz

Glatting

Hoenig

et al. 2011

Blood

View full text Add to dashboard Cite

Radioimmunoimaging for Diagnosis of Bone Marrow Involvement in Breast Cancer and Malignant Lymphoma

Cited by 75 publications

References 15 publications

Radioimmunotherapy with Anti-CD66 Antibody: Improving the Biodistribution Using a Physiologically Based Pharmacokinetic Model

Radioimmunotherapy with Anti-CD66 Antibody: Improving the Biodistribution Using a Physiologically Based Pharmacokinetic Model

Bone Marrow Immunoscintigraphy Compared with Conventional Bone Scintigraphy for the Detection of Bone Metastases

Radioimmunotherapy-based conditioning for hematopoietic cell transplantation in children with malignant and nonmalignant diseases

Contact Info

Product

Resources

About